Pet Cancer Therapeutics Market Expected to Reach $0.7 Billion by 2030 at 11% CAGR

April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Antibody Drug Conjugates Contract Manufacturing Market Between 2026 And 2030?

The pet cancer therapeutics market has experienced substantial growth in recent years. This market is forecasted to increase from $0.43 billion in 2025 to $0.48 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The growth observed in the past can be ascribed to factors such as the rising incidence of cancer among companion animals, the development of conventional chemotherapy protocols, an expansion of veterinary hospital infrastructure, advancements in diagnostic imaging for pets, and an increase in the companion animal population.

The pet cancer therapeutics market size is anticipated to experience significant expansion in the coming years. It is expected to grow to $0.72 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period can be linked to advancements in immunotherapy and targeted therapy, the integration of artificial intelligence in diagnosis and treatment, the expansion of online and retail pharmacy channels, increasing awareness regarding early cancer detection, and rising investment in veterinary oncology research. Prominent trends within the forecast period include the increasing adoption of targeted therapies for pet cancer, a greater use of immunotherapy in companion animals, the expansion of multi-modal cancer treatment protocols, an intensified focus on early cancer detection in pets, and the integration of palliative care into pet oncology.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9984&type=smp

What Major Drivers Are Influencing Demand In The Antibody Drug Conjugates Contract Manufacturing Market?

The rising occurrence of pet cancer is anticipated to drive the expansion of the pet cancer therapeutics market. This condition involves the unchecked growth of abnormal cells in domestic animals like dogs and cats, forming tumors. Environmental toxins and pollutants are primary contributors to this increased prevalence, alongside genetic and lifestyle factors, thereby boosting the need for advanced and effective cancer treatments for pets. Pet cancer therapeutics work by targeting and eliminating cancerous cells or by impeding tumor growth, which in turn enhances survival rates and alleviates discomfort for affected animals. For example, the American Veterinary Medical Association (AVMA) projects that by 2025, approximately 1 in 4 dogs will develop cancer during their lifetime, with this risk increasing to 1 in 2 for dogs over 10 years old. Consequently, the growing incidence of pet cancer will propel the pet cancer therapeutics market growth.

Which Market Segments Are Examined In The Antibody Drug Conjugates Contract Manufacturing Market Study?

The pet cancer therapeutics market covered in this report is segmented –

1) By Cancer Type: Melanoma, Mast Cell Cancer, Lymphoma, Mammary And Squamous Cell Cancer

2) By Species: Dogs, Cats, Other Species

3) By Therapy: Chemotherapy, Radiation Therapy, Immunotherapy, Tomotherapy, Other Therapies

4) By End User: Veterinary Hospitals, Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, Other End Users

Subsegments:

1) By Melanoma: Surgical Interventions, Chemotherapy, Immunotherapy, Targeted Therapy

2) By Mast Cell Cancer: Surgery, Chemotherapy, Tyrosine Kinase Inhibitors, Radiation Therapy

3) By Lymphoma: Chemotherapy Protocols, Steroid Therapy, Radiation Therapy, Immunotherapy

4) By Mammary And Squamous Cell Cancer: Surgical Treatment, Chemotherapy, Radiation Therapy, Palliative Care Options

Which Trends Are Influencing The Pet Cancer Therapeutics Market?

Leading firms in the pet cancer therapeutics market are advancing technologies like epigenetic technology to improve treatment effectiveness and accuracy in targeting cancer cells, thereby enhancing results for pets suffering from cancer. Epigenetic technology describes techniques that alter gene expression without modifying the core DNA sequence, frequently impacting cellular behavior and potential therapeutic effects. For example, in April 2024, VolitionRx Limited, a US-based multi-national epigenetics company, introduced the Nu.Q Vet Cancer Test. This Nu.Q Vet Cancer Test functions on the Element i+ Analyzer, enabling rapid results, generally within around 6 minutes. It uses an enzyme-linked immunosorbent assay to detect circulating nucleosomes in the blood, which may signify the presence of cancer.

Who Are The Primary Competitors In The Antibody Drug Conjugates Contract Manufacturing Market?

Major companies operating in the pet cancer therapeutics market are AB Science, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., Dechra Pharmaceuticals plc, AdvaVet Inc., Oasmia Pharmaceuticals AB, Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc., Boehringer Ingelheim GmbH, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Norbrook Laboratories Ltd., Zenoaq Co. Ltd., Morphogenesis Inc.

Read the full pet cancer therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/pet-cancer-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Antibody Drug Conjugates Contract Manufacturing Market?

North America was the largest region in the pet cancer therapeutics market in 2025. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antibody Drug Conjugates Contract Manufacturing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9984&type=smp

Browse Through More Reports Similar to the Global Pet Cancer Therapeutics Market 2026, By The Business Research Company

Pet Supplements Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pet-supplements-global-market-report

Pet Herbal Supplements Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pet-herbal-supplements-global-market-report

Brain Tumor Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795